Bo Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bo Peng has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Fan Feng
MOE Key Laboratory of Protein Sciences, State Key Laboratory of Molecular Oncology, Beijing Frontier Research Center for Biological Structure, School of Medicine, Tsinghua University, Beijing 100084, China
1 shared publication- Fan Zhao
MOE Key Laboratory of Protein Sciences, State Key Laboratory of Molecular Oncology, Beijing Frontier Research Center for Biological Structure, School of Medicine, Tsinghua University, Beijing 100084, China
1 shared publication - Fen Yang
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, Jiangsu, PR China
1 shared publication - Haitao Li
Tsinghua University
1 shared publication - Juntao Gao
Tsinghua University
1 shared publication - Ke Yao
School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
1 shared publication
Latest Publications
- 15 November 2023
- Published by Elsevier in Journal of Molecular Biology
- Vol. 436 (7) , 168371
Molecular Basis for SPINDOC-Spindlin1 Engagement and Its Role in Transcriptional Attenuation
- 15 November 2023
- Published by Elsevier in Journal of Molecular Biology
- Vol. 436 (7) , 168371
Molecular Basis for SPINDOC-Spindlin1 Engagement and Its Role in Transcriptional Attenuation
- Open Access
- 10 November 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
Evolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinoma
Metabolic reprogramming evolves during cancer initiation and progression. However, thorough understanding of metabolic evolution from preneoplasia to lung adenocarcinoma (LUAD) is still limited. Here, we perform large-scale targeted metabolomics on resected lesions and plasma obtained from invasive LUAD and its precursors, and decipher the metabolic trajectories from atypical adenomatous hyperplasia (AAH) to adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IAC), revealing that perturbed metabolic pathways emerge early in premalignant lesions. Furthermore, three panels of plasma metabolites are identified as non-invasive predictive biomarkers to distinguish IAC and its precursors with benign diseases. Strikingly, metabolomics clustering defines three metabolic subtypes of IAC patients with distinct clinical characteristics. We identify correlation between aberrant bile acid metabolism in subtype III with poor clinical features and demonstrate dysregulated bile acid metabolism promotes migration of LUAD, which could be exploited as potential targetable vulnerability and for stratifying patients. Collectively, the comprehensive landscape of the metabolic evolution along the development of LUAD will improve early detection and provide impactful therapeutic strategies.
- 10 November 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-13
Open AccessEvolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinoma
Metabolic reprogramming evolves during cancer initiation and progression. However, thorough understanding of metabolic evolution from preneoplasia to lung adenocarcinoma (LUAD) is still limited. Here, we perform large-scale targeted metabolomics on resected lesions and plasma obtained from invasive LUAD and its precursors, and decipher the metabolic trajectories from atypical adenomatous hyperplasia (AAH) to adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IAC), revealing that perturbed metabolic pathways emerge early in premalignant lesions. Furthermore, three panels of plasma metabolites are identified as non-invasive predictive biomarkers to distinguish IAC and its precursors with benign diseases. Strikingly, metabolomics clustering defines three metabolic subtypes of IAC patients with distinct clinical characteristics. We identify correlation between aberrant bile acid metabolism in subtype III with poor clinical features and demonstrate dysregulated bile acid metabolism promotes migration of LUAD, which could be exploited as potential targetable vulnerability and for stratifying patients. Collectively, the comprehensive landscape of the metabolic evolution along the development of LUAD will improve early detection and provide impactful therapeutic strategies.